SuperworthTraws Pharma TRAW
- Market cap
- $5.3M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- not a meaningful number
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Traws Pharma's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $57K+0% | $56K+0% | $56K+0% | $57K+0% | $57K+0% | $56K+0% | $57K+2% | $2.7M+4695% | $0 | $0 | n/a | n/a | |
| R&D | $2.5M−32% | $2.4M−36% | $1.9M−53% | $4M+61% | $5.1M+108% | $1.9M−24% | $2.5M+31% | $2.3M−42% | $2.3M−55% | $5M+171% | $4.9M+96% | $1.1M−52% |
| SG&A | $2.7M+28% | $2.1M+3% | $3.4M+59% | $2M−11% | $3.5M+30% | $3.5M+67% | $2.8M−18% | $1.7M−15% | $1.7M−50% | $2.3M−33% | $2M−26% | $3.5M+106% |
| −$5.1M−10% | −$4.5M−22% | −$5.2M−15% | −$123.3M+2576% | −$8.5M+68% | −$5.3M+18% | −$5.2M−0% | −$1.2M−99% | −$4.1M−53% | −$7.4M+40% | −$6.9M+34% | −$3.2M+154% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$4.7M−12% | −$4.2M−23% | −$5M−14% | −$123.1M+2798% | −$8.5M+79% | −$29.9M+615% | $21.5M | −$915K−99% | −$4M−53% | −$7.4M−75% | −$7.1M | −$3.1M+234% |
| −$5.64−13% | −$4.98−23% | −$5.92−15% | −$20.52+310% | −$1.49−74% | −$6.98+40% | $2.09 | −$0.11−100% | −$0.34−77% | −$0.58−92% | −$0.53 | −$0.16+46% | |
| 840.1K+0% | 840.5K+0% | 841.7K+0% | 1M+21% | 961.5K+15% | 3.1M+265% | 7.2M+757% | 5.8M+475% | 8.8M+817% | 9.3M+205% | 10.6M+48% | 15.9M+173% |
Revenue: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.
R&D: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.
SG&A: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.
Operating income: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.
Net income: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.
EPS, diluted: 13 periods, Q1 FY12 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY15 and Q4 FY24: share-days: the 12-month average less the 9-month, weighted by days. 9 periods, Q4 FY16 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Traws Pharma's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| TRAWTraws Pharma | $5.3M | n/m | n/a | n/m | n/m | n/m | |
| OXBROXBRIDGE RE HOLDINGS | $7.7M | 47.5× | 9.6× | 2.8× | +40% | 4.7% | |
| EDUCEducational Development | $8.7M | 5.4× | 11.3× | 0.4× | −32% | 8.6% | |
| GTIMGood Times Restaurants | $13.6M | 6.1× | 13.6× | 0.1× | −6% | 1.7% | |
| MDRRMedalist Diversified | $15.4M | 2.5× | 3.0× | 1.6× | −1% | 80.2% | |
| BCGBinah Capital | $18.2M | 6.7× | 20.8× | 0.1× | +8% | 2.2% | |
| VIPVulcan Infrastructure & Power | $19.6M | 17.9× | 24.4× | 0.4× | −14% | 1.0% | |
| MXCMexco Energy | $20.5M | 13.4× | 13.3× | 3.0× | −9% | 23.3% | |
| CKXCKX Lands | $21.5M | 7.4× | 32.6× | 31.0× | −17% | n/m | |
| MSGMMotorsport Games | $22.5M | 11.4× | 11.5× | 1.5× | +79% | 16.2% | |
| ATCHAtlasClear | $24M | 15.8× | 17.5× | 1.2× | +85% | 9.8% | |
| Peer median | $18.9M | 9.4× | 13.4× | 1.4× | −3% | 8.6% |
More on Traws Pharma
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .